Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Medivir on its divestment of BioPhausia to Karo Pharma
Mandate

Vinge advises Medivir on its divestment of BioPhausia to Karo Pharma

November 03, 2016

Medivir AB (publ) (Nasdaq Stockholm) has entered into an agreement with Karo Pharma AB (publ) (Nasdaq Stockholm) regarding the sale of Medivir’s subsidiary BioPhausia (Nordic Brands) to Karo Pharma. The purchase price is SEK 908 million and the transaction is expected to close by mid-December 2016.
 
Vinge advises Medivir. The Vinge team includes Erik Sjöman, Anna Edström, Mattias Sköld, Dain Hård Nevonen, Rikard Lindahl and Ludvig Frithiof, and Fredrik Dahl and Sara Strandberg (employment law).

Related

Vinge advises Symrise on its public offer for Probi

 Symrise AG has announced a public cash offer to the shareholders of Probi AB (publ) (“Probi”). The offer values Probi at approximately SEK 3,988 million. The shares in Probi are traded on Nasdaq Stockholm, Mid Cap.
November 20, 2024

Vinge advises Oxx in conjunction with an investment in Kodiak Hub

 Kodiak Hub, a Swedish software as a service (SaaS) company, which offers its customers an AI-based software platform, has performed a capital procurement of EUR 6 million. The venture capital fund Oxx, which invests in SaaS companies, is the largest investor.
November 20, 2024

Vinge advises HAKI Safety AB (publ) in connection with the acquisition of Semmco Group Limited

 Semmco Group is a UK market-leading manufacturer and supplier of maintenance platforms and stairs for aircraft and trains.
November 19, 2024